Meeting
2023 ASCO Annual Meeting
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
Authors
Jai Min Ryu
Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Jai Min Ryu , Wonshik Han , Han-Byoel Lee , Sung Gwe Ahn , Hee Jeong Kim , Hyung Seok Park , Ji Soo Choi , Haeyoung Kim , Jeong Eon Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT04993625
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS624)
DOI
10.1200/JCO.2023.41.16_suppl.TPS624
Abstract #
TPS624
Poster Bd #
449b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
Poster
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2014 ASCO Annual Meeting
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
First Author: Kenji Tamura